Director/PDMR Shareholding

RNS Number : 1150E
Hemogenyx Pharmaceuticals PLC
07 February 2018
 

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

 

Director/PDMR Shareholding

 

CEO and Co-founder buys shares

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that on 5 February 2018 Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of the Company, purchased 26,800 ordinary shares of £0.01 in the Company ("Ordinary Shares") at a price of 2.37 pence per Ordinary Share.

 

Following this transaction, Dr Sandler now holds 40,478,010 Ordinary Shares, representing approximately 11.37% of the Company's issued share capital.

 

The Notification of Dealing Forms provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Vladislav Sandler

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer and Co-Founder

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hemogenyx Pharmaceuticals Plc

b)

 

LEI

 

 

n/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each



Identification code

ISIN GB00BYX3WZ24



b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




2.37p

26,800







d)

 

Aggregated information




- Aggregated volume

 N/A - single transaction



- Price




e)

 

Date of the transaction

 

 

5 February 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Dr Robin Campbell, Chairman




Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 




Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar




Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey




Walbrook PR (UK Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893



US Media enquiries


Lowell Goodman

Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net

 

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York.

 

HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care.

 

For more information, visit www.hemogenyx.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIGDDLDGBGIL
UK 100